Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral PCSK9 inhibitor NNC0385-0434 dose–response and safety vs placebo and evolocumab in ASCVD or high ASCVD risk
jRCT2031210399Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 2, randomised, double-blind trial of NNC0385-0434 in atherosclerotic disease, hypercholesterolemia and dyslipidemia (5 arms), sponsored by Novo Nordisk. Primary endpoint: Change in LDL-cholesterol from baseline to week 12. Started Oct 2021; status: completed.
02
Drugs
NNC0385-0434
03
Conditions
atherosclerotic diseasehypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on jRCT2031210399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210399.